UBS AM’s Akcea Therapeutics Inc AKCA Stock Holding History

UBS AM’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,084	Closed	-$166K	–	2521
2020 Q2	$166K	Buy	+12,084	New	+$186K	﹤0.01%	2419
2019 Q2	–	Sell	-7,156	Closed	-$203K	–	2895
2019 Q1	$203K	Buy	+7,156	New	+$208K	﹤0.01%	2454

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS AM's AKCA Position: Q3 2020 in Review

UBS AM sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 12,084 shares — an estimated $166K sold.

UBS AM first reported a position in AKCA in Q1 2019 and held it in 2 quarters. The position peaked at $203K in Q1 2019. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

UBS AM reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
UBS AM sold 12,084 Akcea Therapeutics Inc shares in Q3 2020, an estimated $166K.
UBS AM first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 2 quarters.
UBS AM's Akcea Therapeutics Inc position peaked at $203K in Q1 2019.
98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on UBS AM's 13F filing for Q3 2020, filed 13 Nov 2020.